[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2009005335A - El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. - Google Patents

El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.

Info

Publication number
MX2009005335A
MX2009005335A MX2009005335A MX2009005335A MX2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A
Authority
MX
Mexico
Prior art keywords
treatment
manufacture
pregnane
cns disorders
pharmaceutical composition
Prior art date
Application number
MX2009005335A
Other languages
English (en)
Inventor
Torbjoern Baeckstroem
Gianna Ragagnin
Original Assignee
Umecrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab filed Critical Umecrine Ab
Publication of MX2009005335A publication Critical patent/MX2009005335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen compuestos esferoidales que tienen resistencia creciente contra el metabolismo y solubilidad creciente en agua, junto con métodos para su producción. Estas sustancias son adecuadas para la fabricación de productos farmacéuticos para el tratamiento de trastornos del SNC inducidos por esteroides o relacionados con esteroides y para uso en métodos de prevención, alivio o tratamiento de dichos trastornos.
MX2009005335A 2006-11-21 2007-11-20 El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. MX2009005335A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
PCT/SE2007/050876 WO2008063128A1 (en) 2006-11-21 2007-11-20 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
MX2009005335A true MX2009005335A (es) 2009-06-08

Family

ID=39429970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005335A MX2009005335A (es) 2006-11-21 2007-11-20 El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.

Country Status (16)

Country Link
US (9) US8580983B2 (es)
EP (4) EP2711371B1 (es)
JP (5) JP5386362B2 (es)
AU (1) AU2007322423C1 (es)
BR (2) BR122013033954B8 (es)
CA (2) CA2664126C (es)
DK (3) DK2711371T3 (es)
ES (3) ES2607852T3 (es)
HU (3) HUE036410T2 (es)
IN (1) IN2014DN02014A (es)
MX (1) MX2009005335A (es)
PL (3) PL2711371T3 (es)
PT (1) PT2097437E (es)
RU (1) RU2458065C2 (es)
SI (1) SI2097437T1 (es)
WO (1) WO2008063128A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005335A (es) * 2006-11-21 2009-06-08 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN102753181B (zh) 2010-01-14 2014-09-17 优麦克里尼穆德公司 具有改进的储存特性和溶解度特性的包含3-β-羟基-5-α-孕烷-20-酮的药物组合物
WO2011138460A1 (en) * 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof
EP2753632B1 (en) 2011-09-08 2023-05-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP2925770B1 (en) * 2012-11-28 2017-01-18 Institut National de la Santé et de la Recherche Médicale (INSERM) 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
CN112375115A (zh) 2013-03-13 2021-02-19 萨奇治疗股份有限公司 神经活性甾类化合物及其使用方法
WO2015114308A1 (en) * 2014-01-29 2015-08-06 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK3224269T3 (da) * 2014-11-27 2020-05-25 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
AR103384A1 (es) * 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
RS62220B1 (sr) 2015-07-06 2021-09-30 Sage Therapeutics Inc Oksisteroli i postupci njihovog korišćenja
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
RS63280B1 (sr) 2016-04-01 2022-06-30 Sage Therapeutics Inc Oksisteroli i postupci za njihovu upotrebu
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
ES2968140T3 (es) 2016-10-18 2024-05-08 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2018075699A1 (en) 2016-10-18 2018-04-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR102478510B1 (ko) 2017-02-10 2022-12-16 아사리나 파마 아베 의학적 치료에서 사용하기 위한 3-베타-히드록시-5-알파-프레그난-20-온
EP3579842A4 (en) 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
UA128186C2 (uk) 2017-11-27 2024-05-01 Умекрайн Когнішн Аб ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 3<font face="Symbol">a</font>-ЕТИНІЛ-3<font face="Symbol">b</font>-ГІДРОКСІАНДРОСТАН-17-ОНУ ОКСИМУ
KR20200140832A (ko) 2018-04-05 2020-12-16 아사리나 파마 에이피에스 물질 금단 장애를 치료하기 위한 gaba-a 길항제
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
EP4429669A1 (en) 2021-11-10 2024-09-18 Umecrine AB Steroid as a modulator of gabaa receptor
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
EP4430056A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
EP4389129A1 (en) * 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) * 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) * 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
BR9506779A (pt) * 1994-02-14 1997-10-14 Cocensys Inc Composto composição farmacéutica método para modular o complexo ionóforo receptor gaba-cloreto em um paciente animal pela ligação ao sitio neuroesteróide no dito complexo método para tratar ou evitar estresse ou ansiedade em um paciente animal método para aliviar ou evitar isônia pms ou pnd em um paciente animal método para tratar ou evitar perturbacões na disposicão de ánimo em um paciente animal e método para induzir anestesia em um paciente animal
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT808325E (pt) * 1994-11-23 2001-06-29 Cocensys Inc Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba
CA2223996A1 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE69927960T2 (de) 1998-03-11 2006-07-20 Torbjörn Backström Epiallopregnanolon zur behandlung von krankheiten des cns
AU3467699A (en) * 1998-04-14 1999-11-01 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (en) * 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
DK1812009T3 (da) * 2004-11-18 2013-08-05 Umecrine Ab GABA-steroidantagonister og deres anvendelse til behandling af CNS-lidelser
MX2009005335A (es) 2006-11-21 2009-06-08 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
WO2011138460A1 (en) 2010-05-07 2011-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Progesterone receptor antagonists and uses thereof

Also Published As

Publication number Publication date
EP2097437A4 (en) 2012-12-26
JP2010510210A (ja) 2010-04-02
JP2013173781A (ja) 2013-09-05
US20150315231A1 (en) 2015-11-05
PL2792681T3 (pl) 2017-06-30
EP2711371B1 (en) 2018-01-10
CA2833976A1 (en) 2008-05-29
JP5657052B2 (ja) 2015-01-21
SI2097437T1 (sl) 2015-10-30
CA2664126C (en) 2014-04-29
CA2664126A1 (en) 2008-05-29
BRPI0718945A8 (pt) 2017-09-19
JP2013177411A (ja) 2013-09-09
EP2097437A1 (en) 2009-09-09
US20130281421A1 (en) 2013-10-24
CA2833976C (en) 2016-03-15
US8853190B2 (en) 2014-10-07
HUE026961T2 (en) 2016-07-28
US20140011779A1 (en) 2014-01-09
US20160272670A1 (en) 2016-09-22
US20080119416A1 (en) 2008-05-22
RU2009107537A (ru) 2010-12-27
WO2008063128A1 (en) 2008-05-29
US20130102578A1 (en) 2013-04-25
BR122013033954B1 (pt) 2021-01-12
BR122013033954B8 (pt) 2021-05-25
EP2711371A1 (en) 2014-03-26
JP5386362B2 (ja) 2014-01-15
BRPI0718945B8 (pt) 2021-05-25
BRPI0718945A2 (pt) 2013-12-24
AU2007322423B2 (en) 2013-01-10
IN2014DN02014A (es) 2015-07-10
DK2711371T3 (en) 2018-04-16
PL2711371T3 (pl) 2018-06-29
EP2097437B1 (en) 2015-05-27
HUE036410T2 (hu) 2018-07-30
US8580983B2 (en) 2013-11-12
EP2792681B1 (en) 2016-10-19
AU2007322423C1 (en) 2013-08-15
BRPI0718945B1 (pt) 2020-10-13
JP2013173782A (ja) 2013-09-05
ES2543841T3 (es) 2015-08-24
DK2097437T3 (en) 2015-06-29
HUE033037T2 (hu) 2017-11-28
JP2015147774A (ja) 2015-08-20
PL2097437T3 (pl) 2015-12-31
PT2097437E (pt) 2015-09-15
RU2458065C2 (ru) 2012-08-10
DK2792681T3 (en) 2017-01-23
US20130102579A1 (en) 2013-04-25
EP2711372A1 (en) 2014-03-26
US20140011793A1 (en) 2014-01-09
JP5918170B2 (ja) 2016-05-18
EP2792681A1 (en) 2014-10-22
ES2662500T3 (es) 2018-04-06
ES2607852T3 (es) 2017-04-04
US20140011792A1 (en) 2014-01-09
US9200028B2 (en) 2015-12-01
AU2007322423A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
MX2009005335A (es) El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
EP2056818A4 (en) COMPOSITIONS AND METHODS FOR NEUROPROTECTION
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
EP2099449A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
SI1919450T1 (sl) Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP1857112A4 (en) AGAINST CANCER FOR ORAL USE WITH LIPOSOME-CONTAINING PHYTOSTEROLS AND PREVENTION OR TREATMENT OF CANCER WITH LIPOSOM
WO2008082602A3 (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
SI2027140T1 (sl) Industrijski proces za sintezo 17 alfa -acetoksi-11 beta -(4-(n,n- dimetil-amino)-fenil)-19-norpregna-4,9-dien-3,20-diona in novi intermediati postopka
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing&#39; s syndrome
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
WO2010091299A3 (en) Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d&#39;au moins un de ses constituants
WO2011022838A8 (en) Polyhydroxylated bile acids for treatment of biliary disorders
IL204194A0 (en) Natural brassinosteroids for use for treating hyperproliferation, treating proliferative diseases and reducing adverse effects of steroid dysfunction in mammals, pharmaceutical composition and its use
WO2010042701A3 (en) Corticosteroid compositions for use in treating diseases of the upper and lower airway passages
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
PH12014501074A1 (en) Methods of using a thiazole derivative
WO2007089733A3 (en) Regimens for treatment of conditions related to estrogen deficiency
WO2007108004A8 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
CY1116595T1 (el) Χρηση του πρεγνανιου και στεροειδων ανδροστανιου για την παραγωγη μιας φαρμακευτικης συνθεσεως για την αγωγη διαταραχων του κνς
WO2008098995A3 (en) Genes involved in mitochondrial biogenesis

Legal Events

Date Code Title Description
FG Grant or registration